Altered immune co-inhibitory receptor expression and correlation of LAG-3 expression to disease severity in NMOSD

J Neuroimmunol. 2024 Mar 15:388:578289. doi: 10.1016/j.jneuroim.2024.578289. Epub 2024 Jan 17.

Abstract

Co-inhibitory receptors (CIR)s regulate T cell-mediated immune responses and growing evidence links co-inhibitory receptors to the progression of neuroimmunological diseases. We studied the expression levels of CIRs: TIM-3, TIGIT, PD-1 and LAG-3 in the peripheral blood mononuclear cells (PBMCs) of 30 patients with Neuromyelitis optica spectrum disorder (NMOSD), 11 Multiple sclerosis (MS) patients and 31 Healthy controls (HC). We found that the mRNA expression levels of TIM-3 were significantly increased in NMOSD compared with HC, and increased LAG-3 surface protein expression was also observed on T-cells of NMOSD patients. Moreover, we observed a negative correlation between LAG-3 expression and disease severity in NMOSD. Our findings suggest a protective effect of LAG-3 in the setting of NMOSD, and that the differential expression of CIRs observed in this study may play a role in the pathological process of NMOSD.

Keywords: Biomarker; Co-inhibitory receptor; LAG-3; Multiple sclerosis; Neuromyelitis optica; TIM-3.

MeSH terms

  • Hepatitis A Virus Cellular Receptor 2
  • Humans
  • Leukocytes, Mononuclear / metabolism
  • Multiple Sclerosis*
  • Neuromyelitis Optica*
  • Patient Acuity
  • Receptors, Immunologic / metabolism

Substances

  • Hepatitis A Virus Cellular Receptor 2
  • Receptors, Immunologic
  • Lag3 protein, human